Resveratrol and Type 2 Diabetes

Inclusion Criteria:

• Male sex
• Age: 40-70 years
• Body fat percentage > 25, BMI 27-35 kg/m2
• Diagnosed with type 2 diabetes at least one year before the start of the study
• Well-controlled type 2 diabetics: HBA1C < 8.0%
• Oral glucose lowering medication (metformin only or in combination with sulfonylurea agents)

• Sedentary

  • Not more than 2 hours of sports a week
  • No active job that requires strenuous physical activity
• Stable dietary habits
• Willingness to abstain from resveratrol-containing food products

Exclusion Criteria:

• Unstable body weight (weight gain or loss > 3kg in the last three months)
• Total body fat percentage < 25%
• Hemoglobin < 7.8 mmol/l
• Use of anticoagulants
• Engagement in programmed exercise > 2 hours total per week
• Impaired kidney and/or hepatic function Creatinine 50-100 umol/L Liver enzymes, within 2 times of normal range of laboratory standard (ASAT < 60 U/L, ALAT < 70 U/L, Billi <40 umol/L, gamma-GT < 80 U/L)
• No diabetes related co-morbidities like cardiovascular diseases, diabetic foot, polyneuropathy, retinopathy
• Insulin dependent Diabetic subjects
• Any medical condition except type 2 diabetes mellitus requiring treatment and/or medication use except metformin only or in combination with sulfonylurea agents
• Intake of dietary supplements except multivitamins and minerals
• Current alcohol consumption > 20 grams/day
• Subjects who don't want to be informed about unexpected medical findings during the screening /study, or do not wish that their physician is informed, cannot participate in the study.
• Participation in another biomedical study within 1 month before the first screening visit

• Any contraindication to MRI scanning. These contra-indications include patients with following devices:

  • Central nervous system aneurysm clip
  • Implanted neural stimulator
  • Implanted cardiac pacemaker of defibrillator
  • Cochlear implant
  • Insulin pump
  • Or metal containing corpora aliena in the eye or brains